Ocugen, Inc. (BMV:OCGN) Financings
Financings
| Raise | Date |
|---|---|
| 6.75% convertible senior notes due 2034 Update: US$115M–US$130M Use of proceeds: $32.7 million to retire the Avenue debt; remaining net proceeds for general corporate purposes | May 5, 2026 |
| Public offering of common stock Announced: US$22.5M · US$1.5 a share · Oppenheimer & Co. Dealers: Oppenheimer & Co. (lead) Buyers: RTW Investments Use of proceeds: General corporate purposes, capital expenditures, working capital, and general and administrative expenses | Jan 21, 2026 |
| Registered direct offering of common stock and warrants Closed: US$20M raised · US$1 a share · Warrants at US$1.5 for 24 months · Noble Capital Markets, Inc. +2 Dealers: Noble Capital Markets, Inc. (lead), Maxim Group LLC, Titan Partners Group Buyers: Janus Henderson Investors (20,000,000 shares of common stock and warrants to purchase up to 20,000,000 shares) Use of proceeds: Extend the company's cash runway into the second quarter of 2026 | Aug 12, 2025 |